Association Between Stress Hyperglycemia Ratio and Death in Patients With Moderate to Severe Tricuspid Regurgitation Authors: Ziwei Zhou, Cuiling Li, Shaozhao Zhang, Min Ye, Xinghao Xu, Rui Fan, Yue Guo, Zhenyu Xiong, Menghui Liu, Bingzhen Li, Junqi Zhong, Ziwen Hui, Fengjuan Yao, Xinxue Liao, Xiaodong Zhuang Published: 2026 ABSTRACT BackgroundTricuspid regurgitation (TR) progression correlates with worsened clinical outcomes. The stress hyperglycemia ratio (SHR), a biomarker of acute glycemic dysregulation under stress, has prognostic validity in multiple valvular diseases. This study aims to investigate the correlation between SHR and clinical prognosis in patients with moderate to severe TR.MethodsLeveraging the RED‐CARPET (Real‐World Data of Cardiometabolic Protection) registry from the First Affiliated Hospital of Sun Yat‐sen University, we analyzed 531 patients with moderate‐to‐severe TR categorized into quartiles (quartiles 1–4) by SHR. Primary end points were all‐cause and cardiovascular disease (CVD) death. The association between SHR and death was assessed using a multivariable‐adjusted Cox regression model. The incremental predictive value of incorporating SHR into the traditional risk model was also analyzed.ResultsThe cohort (mean age, 70.93 years) exhibited 38.9% all‐cause deaths (207 events) and 20.0% CVD deaths (106 events) over 5.9‐year median follow‐up. After full adjustment, patients with SHR quartile 4 carried a 108% excess risk of all‐cause death (hazard ratio [HR], 2.08 [95% CI, 1.34–3.23]) and more than twice the hazard of CVD death (HR, 2.40 [95% CI, 1.30–4.43]) versus quartile 1. The addition of SHR into the basic risk model for all‐cause and CVD death improved the concordance statistics (both P<0.001), continuous‐free net reclassification improvement value (P=0.040 for all‐cause death and P=0.046 for CVD death), and integrated discrimination improvement value (P=0.040 for both all‐cause and CVD death).ConclusionsElevated SHR is associated with an increased risk of all‐cause death and CVD death in patients with moderate to severe TR. Nonstandard Abbreviations and Acronyms Real‐World Data of Cardiometabolic Protection stress hyperglycemia ratio tricuspid regurgitation Clinical PerspectiveWhat Is New? To the best of our knowledge, this study is the first to explore the correlation between higher stress hyperglycemia ratio and increased risks of all‐cause and cardiovascular disease death in patients with moderate to severe tricuspid regurgitation.Adding stress hyperglycemia ratio to traditional risk factors modestly improved the prediction of both all‐cause and cardiovascular disease death. What Are the Clinical Implications? This study offers novel clinical insights and targeted management directions for improving prognosis in patients with moderate to severe tricuspid regurgitation, and stress hyperglycemia ratio may serve as a potential tool for risk stratification. Clinical Perspective What Is New? To the best of our knowledge, this study is the first to explore the correlation between higher stress hyperglycemia ratio and increased risks of all‐cause and cardiovascular disease death in patients with moderate to severe tricuspid regurgitation.Adding stress hyperglycemia ratio to traditional risk factors modestly improved the prediction of both all‐cause and cardiovascular disease death. To the best of our knowledge, this study is the first to explore the correlation between higher stress hyperglycemia ratio and increased risks of all‐cause and cardiovascular disease death in patients with moderate to severe tricuspid regurgitation. To the best of our knowledge, this study is the first to explore the correlation between higher stress hyperglycemia ratio and increased risks of all‐cause and cardiovascular disease death in patients with moderate to severe tricuspid regurgitation. Adding stress hyperglycemia ratio to traditional risk factors modestly improved the prediction of both all‐cause and cardiovascular disease death. Adding stress hyperglycemia ratio to traditional risk factors modestly improved the prediction of both all‐cause and cardiovascular disease death. What Are the Clinical Implications? This study offers novel clinical insights and targeted management directions for improving prognosis in patients with moderate to severe tricuspid regurgitation, and stress hyperglycemia ratio may serve as a potential tool for risk stratification. This study offers novel clinical insights and targeted management directions for improving prognosis in patients with moderate to severe tricuspid regurgitation, and stress hyperglycemia ratio may serve as a potential tool for risk stratification. This study offers novel clinical insights and targeted management directions for improving prognosis in patients with moderate to severe tricuspid regurgitation, and stress hyperglycemia ratio may serve as a potential tool for risk stratification. Growing evidence shows that tricuspid regurgitation (TR) independently worsens prognosis, increases morbidity and death, and confers a dose‐dependent rise in death risk. 1 , 2 , 3 , 4 Epidemiological data show that the prevalence of moderate or severe TR in the United States is 0.55%, rising to 4% among adults aged ≥75 years. 5 , 6 In addition to some basic guideline‐directed medical therapies, several therapeutic devices on the market (TriClip, Pascal, Evoque, etc) are available for clinical use. 7 , 8 , 9 , 10 Glycemic fluctuations associate with valvular heart disease onset and progression; emerging data show hyperglycemic states, a marker of systemic metabolic instability, correlate with TR's pathogenesis, progression, and prognosis. 11 , 12 , 13 , 14 Elevated admission blood glucose serves as a manifestation of glucose metabolism dysregulation but fails to adequately reflect a patient's hyperglycemic status due to potential confounding by underlying chronic glycemic conditions. 15 The stress hyperglycemia ratio (SHR) is a validated metric that quantifies acute stress‐induced hyperglycemia. 16 , 17 In recent years, research on SHR has increasingly deepened in the field of valvular heart disease, with its adverse prognostic significance becoming more evident in aortic stenosis and mitral regurgitation. 18 , 19 Given that TR significantly worsens prognosis and reliable risk stratification remains limited, this study explored the association between the SHR and death in patients with moderate to severe TR, aiming to improve the identification of high‐risk individuals (Graphical Abstract). METHODS The data sets used or analyzed during the current study are available from the corresponding author upon reasonable request. Study Design and Study Population The population data for our study were derived from the RED‐CARPET (Real‐World Data of Cardiometabolic Protection) study, a retrospective‐prospective cohort that was registered with the Chinese Clinical Trial Registry (ChiCTR2000039901) and focused on hospitalized patients with cardiometabolic diseases at the First Affiliated Hospital of Sun Yat‐sen University. In the present analysis, we used baseline data collected prospectively within RED‐CARPET and retrospectively adjudicated long‐term mortality outcomes to investigate the prognostic association between SHR and death in patients with moderate to severe TR. This cohort study included a total of 781 patients diagnosed with moderate to severe TR at the First Affiliated Hospital of Sun Yat‐sen University between January 2014 and August 2022. The inclusion criteria were as follows: (1) patients aged ≥18 years and (2) patients diagnosed with moderate to severe TR by echocardiography according to the guidelines. The classification of TR was performed by experienced echocardiographers at the center, and the definitions of TR are as follows: (1): Moderate TR was defined as proximal isovelocity surface area effective regurgitant orifice area: 20 to 39 mm2, vena contracta width: 3 to 6.9 mm, or regurgitant volume: 30 to 44 mL; and (2) severe TR was defined as proximal isovelocity surface area effective regurgitant orifice area ≥40 mm2, VCW ≥7 mm, or regurgitant volume ≥45 mL. 20 , 21 TR was classified according to its mechanism into left‐sided heart‐associated TR (defined as TR that is neither congenital nor organic and occurs in patients with left‐sided valve surgery or intervention, any degree of mitral stenosis, any other native organic valve disease of at least moderate degree, or left ventricular systolic dysfunction with ejection fraction <50%) and non–left‐sided heart associated TR. 22 The exclusion criteria were as follows: (1) lack of baseline data for calculating SHR (n=102); (2) absence of key covariates (n=92); and (3) loss to follow‐up (n=56). Ultimately, 531 patients with moderate to severe TR were included for analysis (Figure 1). Flowchart for the selection of the RED‐CARPET study participants included in the study. RED‐CARPET indicates Real‐World Data of Cardiometabolic Protection. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat‐sen University. Clinical data for this study were collected through electronic medical records, and follow‐up was conducted via telephone. The study received approval for verbal informed consent from the institutional ethics committee, and all participants were enrolled after providing informed consent. Clinical Measurements and Definitions SHR was calculated using the following formula: admission blood glucose (mmol/L)/(1.59×glycated hemoglobin [%] − 2.59). 16 Admission blood glucose is defined as the first blood glucose measurement taken within 24 hours of admission, regardless of fasting status. 19 The blood glucose and glycated hemoglobin levels at admission were obtained from electronic medical records; both parameters were measured in venous blood samples collected and analyzed with an automated biochemical analyzer (Model AU5800; Beckman Coulter, Indianapolis, IN) according to standard techniques. The clinical data of the participants were gathered from electronic medical records, which included self‐reported details such as age, sex, smoking history, and alcohol consumption. Health care professionals measured the blood pressure using a sphygmomanometer after the patients rested for 5 minutes upon waking in the morning. All comorbidities mentioned in the text (Table S1) were diagnosed in accordance with the International Classification of Diseases, Tenth Revision (ICD‐10) coding definitions. Additionally, diabetes was defined as physician‐documented history, glucose‐lowering‐drug use, or baseline glycated hemoglobin ≥6.5%. The presence of atrial fibrillation was determined on the basis of admission ECG or prior documentation in the medical records. In this analysis, coronary artery disease was defined as (1) clinical events of coronary artery disease, such as myocardial infarction (including Q‐wave and non–Q‐wave myocardial infarction); (2) a history of previous coronary revascularization procedures, including coronary artery bypass grafting and percutaneous coronary intervention; and (3) significant stenosis shown on coronary angiography, typically referring to a stenosis degree of ≥50%. Study Outcomes and Follow‐Up The end points of this study include all‐cause death and CVD death. CVD death primarily encompasses deaths resulting from myocardial infarction; congestive heart failure; arrhythmia; invasive cardiovascular procedures; cardiovascular‐related deaths following noncardiac surgeries, strokes, and other vascular conditions such as pulmonary embolism; and sudden deaths believed to be caused by ischemic CVD occurring within 24 hours of symptom onset. Statistical Analysis Normally distributed continuous variables are presented as mean±SD and skewed continuous variables as median (interquartile range), while categorical variables are presented as counts with percentages. The cohort was stratified into quartiles based on SHR levels. Comparative analyses between groups were conducted using 1‐way ANOVA and Tukey's Honestly Significant Difference test for data that were normally distributed and met the homogeneity of variances assumption (as assessed by Levene's test), while Kruskal–Wallis tests with Dunn–Bonferroni post hoc tests were used for data that were skewed or exhibited heterogeneous variances, and Pearson's χ2 tests for categorical variables. Multivariable‐adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for the association between the SHR and death. We applied the Schoenfeld residual test to verify the proportional hazards assumption for the fully adjusted Cox model, confirming that the assumption was met when exploring the association between SHR and clinical outcomes (not shown). The multivariable analysis included clinical variables closely associated with the outcome event, comprising the following covariates: model 1: adjusted for age, sex, and cigarette smoking; model 2: model 1 plus serum creatinine, low‐density lipoprotein cholesterol, history of hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, heart failure, and atrial fibrillation; and model 3: model 2 plus use of an angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, β blocker, or mineralocorticoid receptor antagonist; white blood cell count; alanine aminotransferase; aspartate aminotransferase; insulin; oral hypoglycemic agent; left ventricular ejection fraction; mitral valve disease; pulmonary arterial systolic pressure, glycated hemoglobin; and TR severity. Additionally, Cox regression with Firth's penalized maximum likelihood was used to mitigate overfitting and reduce bias in HR estimation. Competing‐risk analyses (Fine–Gray model) were used to estimate subdistribution HRs for CVD and non‐CVD death associated with SHR. To evaluate a possible nonlinear dose–response association between SHR and the risk of death, we fitted a restricted cubic spline regression with 3 knots positioned. Furthermore, subgroup analyses were conducted based on sex, age (1.21 (n=133) P valueSHR1.05±0.350.70±0.100.90±0.051.09±0.071.51±0.33<0.001Age, y70.93±11.9070.84±11.3071.14±12.3871.50±12.6270.26±11.360.858Sex0.501Male268 (50.5)69 (51.9)59 (44.7)70 (52.6)70 (52.6)Female263 (49.5)64 (48.1)73 (55.3)63 (47.4)63 (47.4)Cigarette smoking120 (22.6)26 (19.5)21 (15.9)36 (27.1)37 (27.8)0.053Alcohol use66 (12.4)14 (10.5)15 (11.4)16 (12.0)21 (15.8)0.577Systolic blood pressure, mm Hg127.26±22.23127.35±21.72128.44±21.51137.32±21.60125.95±24.160.842Chronic obstructive pulmonary disease24 (4.5)4 (3.0)8 (6.1)6 (4.5)6 (4.5)0.698Hypertension321 (60.5)83 (62.4)78 (59.1)76 (57.1)84 (63.2)0.722Diabetes172 (32.4)45 (33.8)42 (31.8)35 (26.3)50 (37.6)0.258Coronary artery disease283 (53.3)73 (54.9)77 (58.3)64 (48.1)69 (51.9)0.389Stroke38 (7.2)8 (6.0)9 (6.8)12 (9.0)9 (6.8)0.799Heart failure393 (74.0)96 (72.2)94 (71.2)99 (74.4)104 (78.2)0.574Atrial fibrillation239 (45.0)57 (42.9)56 (42.4)71 (53.4)55 (41.4)0.165Admission blood glucose, mmol/L* , ‡ 7.94±3.175.73±1.516.76±1.618.23±2.2111.00±3.84<0.001Glycated hemoglobin, %* 6.45±1.336.81±1.436.37±1.126.37±1.246.26±1.460.003White blood cell count, 109/L7.28±2.397.48±2.237.18±2.336.91±2.157.55±2.760.110Serum creatinine, μmol/L* , † , ‡ 94.00 (74.00–130.00)91.00 (71.00–123.50)89.00 (73.00–119.00)93.50 (70.25–127.75)110.00 (84.00–351.60)0.001Total cholesterol, mmol/L* 3.93±1.143.86±1.184.08±1.133.86±1.163.92±1.100.364Low‐density lipoprotein cholesterol, mmol/L* 2.47±0.822.43±0.812.55±0.822.41±0.842.48±0.800.474High‐density lipoprotein cholesterol, mmol/L* , † 1.00±0.320.99±0.331.07±0.310.96±0.300.99±0.320.047Triglyceride, mmol/L* 1.25±0.881.27±0.701.27±0.991.24±1.101.21±0.690.945Lipoprotein(a), mg/dL‡ 14.80 (6.93–31.93)16.40 (6.95–37.33)13.80 (5.70–30.50)13.00 (7.30–27.03)17.40 (8.30–36.05)0.185Alanine aminotransferase, U/L‡ 21.00 (14.00–34.95)19.00 (13.00–31.60)22.00 (14.00–35.00)20.90 (14.00–34.00)24.00 (15.00–39.00)0.197Aspartate aminotransferase, U/L‡ 27.00 (21.00–36.70)26.70 (21.00–35.10)27.00 (21.00–37.00)27.00 (21.00–36.00)27.00 (20.00–38.50)0.915Medication useACEI/ARB/ARNI171 (32.2)36 (27.1)43 (32.6)48 (36.1)44 (33.1)0.461β blocker186 (35.0)41 (30.8)42 (31.8)49 (36.8)54 (40.6)0.303Mineralocorticoid receptor antagonist72 (13.6)18 (13.5)18 (13.6)17 (12.8)19 (14.3)0.988Lipid‐lowering424 (79.8)109 (82.0)104 (78.8)109 (82.0)102 (76.7)0.648Antiplatelet342 (64.4)87 (65.4)85 (64.4)89 (66.9)81 (60.9)0.768Anticoagulant422 (79.5)104 (78.2)102 (77.3)108 (81.2)108 (81.2)0.798Insulin148 (27.9)35 (26.3)30 (22.7)34 (25.6)49 (36.8)0.056Oral hypoglycemic agent178 (33.5)46 (34.6)46 (34.8)40 (30.1)46 (34.6)0.814Left ventricular ejection fraction, %58.62±15.0258.09±15.4859.83±14.9857.72±15.2158.83±14.480.677Interventricular septal thickness, mm10.32±2.0710.55±2.0810.24±1.8210.07±1.7810.44±2.510.553Pulmonary arterial systolic pressure, mm Hg46.39±11.8546.01±11.2747.50±13.1845.05±10.7147.01±12.080.342Superior–inferior diameter of the right atrium, mm56.30±10.9356.37±11.8356.51±10.2457.38±11.8554.93±9.600.329Medial–lateral diameter of the right atrium, mm43.51±9.1743.20±9.9144.25±9.3343.92±8.7042.68±8.700.498Internal diameter of the pulmonary artery, mm24.98±4.1524.50±3.7725.27±4.7025.26±4.5124.88±3.500.373Right ventricular internal diameter, mm24.67±5.0424.50±5.3425.31±5.6424.68±4.8724.20±4.200.327Moderate to severe mitral regurgitation270 (50.8)68 (51.1)60 (45.5)67 (50.4)75 (56.4)0.364Mild to severe mitral stenosis34 (6.4)7 (5.3)9 (6.8)6 (4.5)12 (9.0)0.450TR grade0.818Moderate394 (74.2)101 (75.9)100 (75.8)98 (73.7)95 (71.4)Severe137 (25.8)32 (24.1)32 (24.2)35 (26.3)38 (28.6)TR mechanism0.146Left‐sided heart–associated TR313 (58.9)70 (52.6)75 (56.8)80 (60.2)88 (66.2)Non–left‐sided heart–associated TR218 (41.1)63 (27.4)57 (43.2)53 (39.8)45 (33.8)Data are presented as means±SD, median (interquartile range) or frequency (%). The remaining continuous variables in the table were analyzed using ANOVA, and categorical variables using Pearson's χ2 tests.ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation.*Admission blood glucose: mmol/L (mg/dL × 0.0555); creatinine: μmol/L (mg/dL × 88.4); total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol: mmol/L (mg/dL × 0.0259); triglycerides: mmol/L (mg/dL × 0.0113); glycated hemoglobin: (1% = 10.93 mmol/mol − 23.50). † Tukey's Honestly Significant Difference post hoc test showed significantly higher high‐density lipoprotein cholesterol levels in quartile 2 compared with quartile 4 (P=0.042); all other pairwise comparisons were non‐significant (P>0.05). Dunn–Bonferroni post hoc test demonstrated that serum creatinine levels in quartile 4 were significantly different from those in quartile 1 (P=0.004), quartile 2 (P=0.006), and quartile 3 (P = 0.013), whereas no significant differences were found among quartile 1, quartile 2, and quartile 3. ‡ Kruskal–Wallis test: data that were skewed or exhibited heterogeneous variances. Baseline Clinical Features of Patients Stratified by SHR Quartile Data are presented as means±SD, median (interquartile range) or frequency (%). The remaining continuous variables in the table were analyzed using ANOVA, and categorical variables using Pearson's χ2 tests. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation. Admission blood glucose: mmol/L (mg/dL × 0.0555); creatinine: μmol/L (mg/dL × 88.4); total cholesterol, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol: mmol/L (mg/dL × 0.0259); triglycerides: mmol/L (mg/dL × 0.0113); glycated hemoglobin: (1% = 10.93 mmol/mol − 23.50). Tukey's Honestly Significant Difference post hoc test showed significantly higher high‐density lipoprotein cholesterol levels in quartile 2 compared with quartile 4 (P=0.042); all other pairwise comparisons were non‐significant (P>0.05). Dunn–Bonferroni post hoc test demonstrated that serum creatinine levels in quartile 4 were significantly different from those in quartile 1 (P=0.004), quartile 2 (P=0.006), and quartile 3 (P = 0.013), whereas no significant differences were found among quartile 1, quartile 2, and quartile 3. Kruskal–Wallis test: data that were skewed or exhibited heterogeneous variances. Association of SHR With Death in Moderate and Severe TR During a median follow‐up of 5.9 years, a total of 207 all‐cause mortality events were observed, accounting for 38.9%, including 106 cases (19.9%) of CVD death. As shown in Table 2, the quartile 4 group had the highest rates of both all‐cause and CVD death, with a gradual decrease in mortality rates observed as the SHR quartiles decreased. The Kaplan–Meier analysis showed that all‐cause death in the highest SHR quartile (quartile 4) differed significantly from that in the remaining groups (P=0.024), whereas the log‐rank test for CVD death was marginally nonsignificant (P=0.069; Figure S1). After adjusting for several key clinical variables, the Cox regression analysis revealed that compared with the quartile 1 group, the quartile 4 group exhibited a significantly increased risk of all‐cause death (HR, 2.08 [95% CI, 1.34–3.23]; P=0.001) and a 2.40‐fold increase in the risk of CVD death (HR, 2.40 [95% CI, 1.30–4.43]; P=0.005; Table 2). When treated as a continuous variable, each 1‐unit increase in SHR was associated with a 68% increase in all‐cause mortality risk (HR, 1.68 [95% CI, 1.13–2.52]) and a 108% increase in CVD mortality risk (HR, 2.08 [95% CI, 1.17–3.71]). Restricted cubic spline analysis illustrated the adjusted HR for all‐cause and CVD death across the full spectrum of SHR values (Figure S2). For all‐cause death and CVD death, the restricted cubic spline analysis revealed a statistically significant overall association between SHR and the adjusted HR (P‐overall=0.011–0.012). Table 2Association Between SHR and Death: Multivariate Cox Regression AnalysisEvents/total (%)Model 1Model 2Model 3HR (95% CI) P valueHR (95% CI) P valueHR (95% CI) P valueAll‐cause deathContinuous207/531 (38.9)1.81 (1.27–2.59)0.0011.52 (1.05–2.20)0.0281.68 (1.13–2.52)0.011Quartile 135/133 (26.3)ReferenceReferenceReferenceQuartile 253/132 (40.1)1.71 (1.11–2.62)0.0141.71 (1.11–2.63)0.0151.91 (1.23–2.97)0.004Quartile 358/133 (43.6)1.93 (1.27–2.95)0.0021.90 (1.24–2.92)0.0031.91 (1.23–2.97)0.004Quartile 461/133 (45.8)2.23 (1.46–3.38)<0.0011.94 (1.27–2.98)0.0022.08 (1.34–3.23)0.001 P for trend<0.0010.0030.002CVD deathContinuous106/531 (20.0)1.88 (1.15–3.10)0.0131.69 (1.02–2.82)0.0442.08 (1.17–3.71)0.013Quartile 118/133 (13.5)ReferenceReferenceReferenceQuartile 228/132 (21.2)1.70 (0.94–3.07)0.0811.71 (0.94–3.11)0.0802.05 (1.10–3.79)0.023Quartile 328/133 (21.0)1.80 (0.99–3.27)0.0531.90 (1.04–3.47)0.0371.84 (0.98–3.44)0.057Quartile 432/133 (24.0)2.24 (1.25–4.00)0.0072.13 (1.17–3.85)0.0132.40 (1.30–4.43)0.005 P for trend0.0080.0140.012Model 1: adjusted for age, sex, and cigarette smoking. Model 2: model 1 plus serum creatinine, low‐density lipoprotein cholesterol, history of hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, heart failure, and atrial fibrillation. Model 3: model 2 plus use of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, β blocker, mineralocorticoid receptor antagonist, white blood cell count, alanine aminotransferase, aspartate aminotransferase, insulin, oral hypoglycemic agent, left ventricular ejection fraction, mitral valve disease, pulmonary arterial systolic pressure, glycated hemoglobin, and TR severity.CVD indicates cardiovascular disease; HR, hazard ratio; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation. Association Between SHR and Death: Multivariate Cox Regression Analysis Model 1: adjusted for age, sex, and cigarette smoking. Model 2: model 1 plus serum creatinine, low‐density lipoprotein cholesterol, history of hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, heart failure, and atrial fibrillation. Model 3: model 2 plus use of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, β blocker, mineralocorticoid receptor antagonist, white blood cell count, alanine aminotransferase, aspartate aminotransferase, insulin, oral hypoglycemic agent, left ventricular ejection fraction, mitral valve disease, pulmonary arterial systolic pressure, glycated hemoglobin, and TR severity. CVD indicates cardiovascular disease; HR, hazard ratio; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation. As shown in Table S3, Firth‐penalized Cox regression again demonstrated that each 1‐unit rise in SHR was significantly linked to a higher mortality rate: all‐cause death increased by 71% (HR, 1.71 [95% CI, 1.12–2.52]; P=0.019) and CVD death by 113% (HR, 2.13 [95% CI, 1.17–3.73]; P=0.014). Fine–Gray competing‐risk analysis confirmed a significant subdistribution hazard association between SHR and CVD death after full adjustment (HR, 2.23, 95% CI 1.19–4.15, P=0.012), mirroring the primary Cox findings and indicating that competing risks did not materially alter the results (Table S4). Additional Analyses Subgroup analyses were conducted on the basis of sex (female or male), age (≥ 65 or <65 years), diabetes (yes or no), heart failure (yes or no), TR grade (moderate or severe) and TR mechanism (left‐sided heart–associated TR or non–left‐sided heart–associated TR) (Figure 2). After adjustment for potential confounders across all subgroups, the association between SHR and death remained consistent, with no significant interaction detected (all P‐interaction >0.05), thereby validating the robustness of our main finding. Considering that left‐sided valvular procedures might influence the mortality rate, we added them to the model as an additional time‐dependent variable; the results remained consistent with the main findings (Table S5). After including the 92 participants with missing key covariates and reassigning SHR quartiles, elevated SHR remained significantly associated with increased mortality risk (all‐cause death: HR, 2.00 [95% CI, 1.28–3.13]; CVD death: HR, 3.13 [95% CI, 1.61–6.07]; Table S6). Subgroup analysis of the association between baseline SHR and incidence of all‐cause death (A) and CVD death (B). CVD indicates cardiovascular disease; HR, hazard ratios; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation. Incremental Predictive Value of SHR Incorporating SHR into the established multivariable Cox model significantly improved risk prediction for both end points (Table 3). For all‐cause death, the net reclassification improvement was 0.154 (P=0.040), and the integrated discrimination improvement was 0.012 (P=0.040); the concordance index rose from 0.715 (0.679–0.750) to 0.721 (0.686–0.756). For CVD death, the corresponding gains were 0.196 (P=0.046) and 0.015 (P=0.040), with the concordance index increasing from 0.770 (0.728–0.812) to 0.777 (0.735–0.820). Calibration curves confirmed that the SHR‐enhanced model delivered the best overall predictive performance (Figure S3). Table 3Performance of the Model With SHR to Predict All‐Cause Death and CVD Death in Patients With Moderate and Severe TRConcordance indexContinuous‐free net reclassification improvementIntegrated discrimination improvementIndex P valueIndex P valueIndex P valueAll‐cause deathBasic model0.715 (0.679–0.750)<0.001ReferenceReferenceBasic model+SHR0.721 (0.686–0.756)<0.0010.154 (0.002–0.262)0.0400.012 (0.001–0.034)0.040CVD deathBasic model0.770 (0.728–0.812)<0.001ReferenceReferenceBasic model+SHR0.777 (0.735–0.820)<0.0010.196 (0.003–0.326)0.0460.015 (0.001–0.041)0.040The basic model included age, sex, cigarette smoking, serum creatinine, low‐density lipoprotein cholesterol, history of hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, heart failure, atrial fibrillation, use of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, β blocker, mineralocorticoid receptor antagonist, white blood cell, alanine aminotransferase, aspartate aminotransferase, insulin, oral hypoglycemic agent, left ventricular ejection fraction, mitral valve disease, pulmonary arterial systolic pressure, glycated hemoglobin, and TR severity.CVD indicates cardiovascular disease; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation. Performance of the Model With SHR to Predict All‐Cause Death and CVD Death in Patients With Moderate and Severe TR The basic model included age, sex, cigarette smoking, serum creatinine, low‐density lipoprotein cholesterol, history of hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, heart failure, atrial fibrillation, use of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, β blocker, mineralocorticoid receptor antagonist, white blood cell, alanine aminotransferase, aspartate aminotransferase, insulin, oral hypoglycemic agent, left ventricular ejection fraction, mitral valve disease, pulmonary arterial systolic pressure, glycated hemoglobin, and TR severity. CVD indicates cardiovascular disease; SHR, stress hyperglycemia ratio; and TR, tricuspid regurgitation. DISCUSSION To the best of our knowledge, our study is the first to reveal the association between SHR and mortality risk in patients with moderate to severe TR. The results indicated that a higher SHR was significantly associated with increased risks of all‐cause death and CVD death in this population. Additionally, incorporating SHR into the traditional risk‐factor model provided modest incremental predictive value for both all‐cause and CVD death. Moderate to severe TR is a prevalent valvular heart disease, with 2019 data indicating a community‐based prevalence of ≈0.55%. Notably, its prevalence escalates with advancing age, reaching a striking 3.96% in individuals aged >75 years. Data from China reveal that TR is the second most prevalent valvular lesion, following mitral regurgitation, among older hospitalized patients with primary valvular heart disease. 23 Patients often experience a markedly reduced quality of life due to symptoms such as fatigue and edema, and those with moderate to severe TR demonstrate significantly higher mortality rates compared with individuals without TR or with mild TR. 22 Given the elevated risks associated with this specific population, it is recommended that patients with moderate or greater TR undergo further risk stratification and management. The treatment of TR is complex and requires a comprehensive approach to manage underlying conditions and to control modifiable risk factors. 24 Abnormal glucose metabolism is associated with various valvular diseases and can exacerbate cardiac remodeling and functional impairments beyond valvular abnormalities, leading to poor prognosis. 25 , 26 For example, a survey study with a sample size exceeding 10 000 participants demonstrated a significant burden of diabetes in patients with TR, and diabetes was found to be a predictor of poor outcomes in this population, including increased mortality rates. 13 Additionally, the complications arising from dysglycemia may pose additional risks during surgery, making meticulous risk management essential for patients with TR. 23 SHR is an indicator that reflects fluctuations in blood glucose levels under disease conditions. It partially represents the true state of glucose metabolism disturbances, inflammatory burden, and disease status, and holds significant importance for the assessment of clinical prognosis. 16 In fact, a series of studies have confirmed a significant association between the SHR and adverse outcomes in CVD. A meta‐analysis that included 10 cohort studies on heart failure populations indicated that a high baseline SHR in patients with heart failure is associated with a higher likelihood of all‐cause death and CVD death. 27 This is consistent with our prespecified clinical outcomes. Stress hyperglycemia is also common in the atherosclerotic CVD population and significantly predicts both short‐ and long‐term adverse outcomes. 28 , 29 , 30 , 31 , 32 In recent years, there has been an increasing number of studies on the correlation between stress hyperglycemia and valvular heart disease, and its potential role in CVD risk stratification for patients with valvular disease is becoming increasingly recognized in the academic community. In a study conducted in 2024 involving 582 patients with severe AS who underwent transcatheter aortic valve replacement, researchers found that during nearly 4 years of follow‐up, SHR was independently associated with all‐cause death, CVD death, heart failure readmission rates, and major adverse cardiovascular events. 18 This suggests that SHR, as a simple indicator, can be used to identify high‐risk adverse prognoses in patients with aortic valve disease. Similarly, in the mitral regurgitation cohort, it was revealed that SHR is a significant independent predictor of the worsening of heart failure in patients with mitral regurgitation. 19 In summary, these results suggest that high SHR may be an indicator of poor prognosis in patients with valvular heart disease. However, current studies still lack direct assessments of the relationship between SHR and death in patients with moderate to severe TR. Our study first demonstrated that after adjusting for some potential confounding factors in patients with moderate to severe TR, glycemic fluctuation assessed by SHR is significantly associated with a higher risk of all‐cause death and CVD death (Graphical Abstract). Subgroup analyses conducted on common clinical variables generally showed results consistent with the primary findings. Incorporating SHR into the traditional risk‐prediction model modestly improved the discriminative power for both all‐cause and CVD death, indicating that SHR can serve as a complementary risk stratification tool rather than a stand‐alone decision tool. The moderate to severe TR population itself represents a high‐risk group; therefore, optimizing risk management and implementing tailored interventions for patients at potential risk of adverse outcomes, such as enhancing right heart function, controlling volume overload, targeted glycemic control, and interventional therapies, may contribute to improving patient prognosis before severe events occur. Our findings offer new preliminary clinical evidence for subsequent research on the role of glycemic metabolic disorders in the prognosis of patients with TR, and future research could explore strategies to improve prognosis by lowering SHR, such as enhancing hemodynamics or implementing anti‐inflammatory therapies. The specific mechanisms by which stress hyperglycemia is associated with mortality prognosis in patients with moderate to severe TR are still in the exploratory phase. Stress hyperglycemia may be mediated by severe inflammation and neuroendocrine dysregulation, which can exacerbate multiple‐organ failure and endothelial dysfunction. Glucose fluctuations and oxidative stress are also highlighted as important factors, particularly in relation to endothelial cell apoptosis and dysfunction. 33 In addition, preexisting microvascular and macrovascular lesions in patients may increase the risk of hypoglycemia, which in turn heightens the risk of inflammation and arrhythmias. 34 This study has several limitations. First, despite adjustments for several important clinically relevant variables such as white blood cell count, residual confounding by heart failure severity and systemic illness may persist. Second, while pulmonary arterial systolic pressure was included in the Cox model as an indicator of right ventricular afterload, direct measures of right ventricular function (eg, tricuspid annular plane systolic excursion, right ventricular fractional area change, and right ventricular strain) were not available in this study, despite being key prognostic factors in patients with TR. Third, while admission blood glucose was operationalized as the first blood glucose measurement within the initial 24 hours of admission, the nonstandardized timing of this measurement relative to hospital admission introduces residual uncertainty. Fourth, this is a single‐center study, and further exploration is needed to determine whether the conclusions are applicable to other populations. Fifth, as a retrospective‐prospective cohort study, our analysis may still include inherent limitations, such as the inability to establish causal relationships and missing clinical data. Therefore, further prospective clinical and mechanistic studies are needed to clarify the causal links and pathophysiology between stress hyperglycemia and clinical outcomes. Conclusions To our knowledge, our study is the first to confirm a significant association between SHR and adverse outcomes in patients with moderate to severe TR. Elevated SHR may serve as a potential predictor of increased mortality risk in this population. These findings provide new clinical insights and targeted risk management strategies for improving the prognosis of patients with moderate to severe TR. Sources of Funding This study was supported by the National Natural Science Foundation of China (82 400 495 to M.L.; 82 470 361 to Y.G; 82 370 358 to X.L.), Guangdong Basic and Applied Basic Research Foundation (2024A1515013234 to X.L.; 2024A1515012356 to X.Z.; 2024A1515030241 to Y.G.; 2022A1515111181 to M.L.; 2023A1515011294 to F.Y.), Funding by Science and Technology Projects in Guangzhou (2023A04J2169 to Y.G.), Youth S&T Talent Support Programme of Guangdong Provincial Association for Science and Technology (SKXRC2025559 to Y.G.), and Young Talent Support Project of Guangzhou Association for Science and Technology (QT2024‐029 to Y.G.). Disclosures None. Supporting information Table S1–S6 Figure S1–S3 Strobe Check list